Filing Flows › Bolt Biotherapeutics (BOLT) › R&D spending
Bolt Biotherapeutics (BOLT) R&D spending by quarter
Bolt Biotherapeutics' R&D spending was $5.1M in Q2 2026 (second quarter 2026), +7% from Q1 2026. Over the last 6 quarters it ranged from $4.8M (Q1 2026) to $9.5M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $5.1M | +7% | -31% |
| Q1 2026 | $4.8M | -3% | -49% |
| Q4 2025 | $5.0M | -24% | — |
| Q3 2025 | $6.5M | -13% | — |
| Q2 2025 | $7.5M | -21% | — |
| Q1 2025 | $9.5M | — | — |
Q2 2026 at a glance
Bolt Biotherapeutics, Q2 2026: revenue $5K (-100% year over year), net loss $7.7M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Bolt Biotherapeutics' R&D spending?
Bolt Biotherapeutics' R&D spending was $5.1M in Q2 2026 (second quarter 2026), +7% from Q1 2026.
How has Bolt Biotherapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $4.8M (Q1 2026) to $9.5M (Q1 2025).